RELEASE: Cambrex recognized with the CDMO Leadership Awards for the 9th consecutive year

(Information sent by the signatory company).

RELEASE: Cambrex recognized with the CDMO Leadership Awards for the 9th consecutive year

(Information sent by the signatory company)

EAST RUTHERFORD, N.J., March 1, 2023 /PRNewswire/ -- Cambrex, a leading global contract development and manufacturing organization (CDMO), announced today that it has been recognized with the 2023 CDMO Leadership Awards in the categories of Quality, Service, Experience and Compatibility. In addition, Cambrex was selected as "Champion" in the Service category. This is the ninth consecutive year that Cambrex has been recognized with an award.

"Cambrex is honored to be selected by our customers as a leading supplier to the pharmaceutical industry," said Thomas Loewald, CEO of Cambrex. He added: "While we are pleased to be recognized in four categories this year, we are particularly proud to be recognized as Champion in the Service category, as it reflects our goal of delivering a consistently superior customer experience."

Results for the CDMO Leadership Awards are based on primary market research from Industry Standard Research's Contract Manufacturing Quality Benchmarking surveys. For the 2023 CDMO Leadership Awards, 72 CDMOs were evaluated on 23 performance metrics. Respondents only evaluated companies with which they had worked on an outsourced project in the past 18 months. This level of qualification ensures that assessments come from actual engagement with a company and that companies identified as leaders are backed by experiential data.

"For more than a decade, these awards have been the most significant for biopharmaceutical organizations striving to obtain optimal results from their outsourcing activities. Our research arm, ISR Reports, which only surveys drug sponsors who have worked directly and recently with specific CDMOs, ensures the validity of these results. Our winners are the outsourcing gold medalists." Louis Garguilo, Editor-in-Chief and Conference Chair, Outsourced Pharma.

Cambrex continues to invest to support its commitment to leadership in pharmaceutical development and manufacturing, including more than $100 million in recent capacity expansions and the addition of new services and technical capabilities through the acquisitions of Snapdragon Chemistry and Q1 Scientific.

About Cambrex

Cambrex is a world-leading contract development and manufacturing organization (CDMO) providing pharmaceutical, substance and analytical services throughout the entire drug lifecycle. With more than 40 years of experience and a growing team of more than 2,400 experts serving global customers in North America and Europe, Cambrex is a trusted partner in the brand and generic markets for the development and manufacturing of APIs and dosage forms. finished.

Cambrex offers a range of specialized pharmaceutical substance technologies and capabilities, including continuous flow, controlled substances, solid state science, materials characterization, stability storage, and highly potent APIs. In addition, Cambrex can support conventional dosage forms, including oral solids, semi-solids, and liquids, and has the expertise to manufacture specialized dosage forms such as modified-release, fixed-dose combination, pediatric, bilayer tablets, stick packs, topicals, controlled substances, sterile and non-sterile ointments.

Logo -

View original content: